Lenz Therapeutics(NASDAQ) LENZ

Lenz makes eye drops that help adults see clearly up close. These drops treat presbyopia, a common condition where the eye loses its ability to focus on nearby objects. The company aims to provide a daily treatment that removes the need for reading glasses.

Clear Vision in a Bottle

• VIZZ: A once-daily eye drop that restores near vision for up to 10 hours; generated $1.7 million in net product sales in Q1 2026.
• LNZ101: A secondary product candidate currently undergoing Phase III clinical trials for the treatment of near-vision loss.
• International Licenses: Rights granted to regional partners for the sale of vision therapies in China, Southeast Asia, Canada, and the Middle East.

Expanding the Global Reach

• Partnered with CORXEL Pharmaceuticals in April 2022 to develop and sell vision products in Greater China.
• Signed a deal with Lotus Pharmaceutical in May 2025 to commercialize VIZZ across eight countries in Southeast Asia.
• Entered a license agreement with Laboratoires Thea in July 2025 to bring VIZZ to the Canadian market.
• Appointed Lunatus Global Medical Supplies in January 2026 as the exclusive distributor for VIZZ in the Middle East.
• Expanded the United States sales force from 88 territories to 117 territories to support the commercial launch of VIZZ.

How the Pinhole Effect Works

Lenz uses a drug called aceclidine that narrows the pupil to create a pinhole effect, which improves focus for near vision. This specific approach aims to improve sight without causing the blurry distance vision often associated with other treatments.

By the Numbers

• Total revenue reached $1.9 million in Q1 2026, up from zero in Q1 2025.
• Net loss deepened to $41.5 million in Q1 2026, worsening 183.8% from the $14.6 million loss in Q1 2025.
• Selling, general, and administrative expenses rose to $45 million in Q1 2026, up from $11.1 million a year earlier.
• Cash and marketable securities totaled $258.4 million as of March 31, 2026, a decrease from $305.9 million in December 2025.
• Free cash flow was negative $33.6 million in Q1 2026, worsening 107.9% compared to negative $16.2 million in Q1 2025.

The Final Word

Lenz has evolved from a research-focused startup into a commercial pharmaceutical company with the launch of its first approved eye drop. Its future depends on scaling its United States sales force and leveraging international partnerships to treat age-related vision loss.